MedTrace Logo

Safety Study of Sorafenib With Androgen Deprivation and Radiotherapy to Treat Prostate Cancer

NCT00924807 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 4

Last updated 2018-12-11

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the safety of a new drug- sorafenib, which is to be administered at the same time as standard treatment, which includes hormonal therapy and external beam radiotherapy.

Conditions

Interventions

DRUG

Leuprolide acetate, Bicalutamide, Sorafenib

Leuprolide acetate - depot, Bicalutamide 50 mg, Sorafenib 400mg

Sponsors & Collaborators

  • Bayer

    collaborator INDUSTRY

  • Beth Israel Medical Center

    lead OTHER

Principal Investigators

  • Seth Cohen, MD · St. Luke's-Roosevelt Hospital Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-09-30
Primary Completion
2013-12-31
Completion
2013-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00924807 on ClinicalTrials.gov